SGLT Inhibitors in Type 1 Diabetes: What Adults Need to Know About Benefits and Safety

Sodium-glucose cotransporter inhibitors (SGLT inhibitors, or SGLTi) are medications that help the body remove excess glucose through urine. They were first developed and approved for treating Type 2 diabetes, but researchers have been investigating whether they might also benefit some adults living with Type 1 diabetes.

Unlike Type 2 diabetes, Type 1 is an autoimmune condition where the body's immune system destroys insulin-producing cells. This means people with Type 1 must take insulin to survive. The question researchers are asking is whether adding an SGLT inhibitor to an insulin regimen could provide extra protection for the heart and kidneys.

A recent clinical guidance review published in Endocrinology and Metabolism Clinics of North America found that SGLT inhibitors, when used as an add-on to insulin therapy, may offer cardiometabolic and renal benefits—meaning they could help protect heart function and kidney health in adults with Type 1 diabetes.

This is significant because people with Type 1 diabetes face higher risks of heart disease and kidney damage over time. Any medication that might reduce those risks is worth studying carefully. However, the potential benefits come with important safety considerations that cannot be overlooked.

SGLT inhibitors carry a specific and serious risk when used in Type 1 diabetes: diabetic ketoacidosis (DKA). DKA occurs when the body breaks down fat too quickly, producing acids called ketones that accumulate in the blood to dangerous levels. It is a medical emergency that can be life-threatening.

Because of this risk, the clinical guidance emphasizes that safe use of SGLT inhibitors in Type 1 diabetes requires structured ketone monitoring, patient education, and strict DKA prevention protocols. This is not a medication someone can start and forget about—it demands active, ongoing management.

If a healthcare provider determines that an SGLT inhibitor might be appropriate for an individual with Type 1 diabetes, the clinical guidance outlines essential steps for safe use. These include starting with the lowest effective dose, making careful adjustments to insulin doses under medical supervision, and following structured protocols for ketone monitoring.

Patient selection is critical. Not everyone with Type 1 diabetes is a candidate for this approach. Success depends on the person's ability to understand the risks, monitor their ketone levels as directed, and follow a structured protocol closely. This is a partnership between patient and healthcare team.

If you have Type 1 diabetes and have heard about SGLT inhibitors, the takeaway is this: they show promise as a potential way to support heart and kidney health when used alongside insulin. However, they are not right for everyone, and they require careful medical supervision and patient commitment to safety protocols.

If you are interested in learning whether an SGLT inhibitor might be appropriate for your situation, talk with your diabetes care team. They can evaluate your individual health profile, discuss the benefits and risks, and help you decide if this approach makes sense for you.

Source: Endocrinology and metabolism clinics of North America. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.